{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:09:30Z","timestamp":1790111370212,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["314984"],"award-info":[{"award-number":["314984"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["8256828"],"award-info":[{"award-number":["8256828"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101098944"],"award-info":[{"award-number":["101098944"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115146","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:08:42Z","timestamp":1781050122000},"page":"115146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interactions between mRNA lipid nanoparticles and immune cells in fresh human whole blood"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-2802","authenticated-orcid":false,"given":"Sjoerd","family":"Hak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-7565","authenticated-orcid":false,"given":"Francesca","family":"Rod\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Molska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"de Carlos Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8913-7462","authenticated-orcid":false,"given":"Camilla","family":"Wolowczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Giambelluca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-896X","authenticated-orcid":false,"given":"Wilhelm R.","family":"Glomm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6222-9252","authenticated-orcid":false,"given":"Sven Even","family":"Borgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-1631","authenticated-orcid":false,"given":"Jeremie","family":"Parot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejpb.2026.115146_b0005","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2026.115146_b0010","unstructured":"Biotechnology Innovation Organization. Clinical Development Success Rates and Contributing Factors 2011-2020; 2021."},{"key":"10.1016\/j.ejpb.2026.115146_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2024.1355044","article-title":"The (Misleading) role of animal models in drug development","volume":"4","author":"Hartung","year":"2024","journal-title":"Front. Drug Discov."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115146_b0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/vaccines13040339","article-title":"Exploring the challenges of lipid nanoparticle development: the in vitro\u2013in vivo correlation gap","volume":"13","author":"Lindsay","year":"2025","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115146_b0025","first-page":"845","article-title":"Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach?","volume":"4","author":"Van Norman","year":"2019","journal-title":"JACC: basic to Translational Science"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115146_b0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the Clinic","volume":"1","author":"Anselmo","year":"2016","journal-title":"Bioeng. Transl. Med."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115146_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the Clinic: an Update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ejpb.2026.115146_b0040","series-title":"Guidance for Industry \u2013 Preclinical Assessment of Investigational Cellular and Gene Therapy Products","article-title":"Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research","author":"U.s.","year":"2013"},{"key":"10.1016\/j.ejpb.2026.115146_b0045","article-title":"Lipid Nanoparticle-Mediated mRNA delivery to CD34+ Cells in Rhesus Monkeys","author":"Kim","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115146_b0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41565-023-01548-3","article-title":"Combinatorial Development of Nebulized mRNA delivery Formulations for the Lungs","volume":"19","author":"Jiang","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"34","key":"10.1016\/j.ejpb.2026.115146_b0055","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing in Vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115146_b0060","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3390\/vaccines12050528","article-title":"The Platform Technology Approach to mRNA Product Development and Regulation","volume":"12","author":"Skerritt","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.ejpb.2026.115146_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The Role of Lipid Components in Lipid Nanoparticles for Vaccines and Gene Therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115146_b0070","first-page":"1","article-title":"Adverse Effects of Intravenous LNP-Mediated mRNA Therapy in Clinical Trials: a Systematic Review and Meta-Analysis","author":"Wu","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115146_b0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in Vivo CAR T Cell Engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"6576","key":"10.1016\/j.ejpb.2026.115146_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T Cells Produced in Vivo to Treat Cardiac Injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115146_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350519","article-title":"Whole Blood Stimulation as a Tool for Studying the Human Immune System","volume":"54","author":"M\u00fcller","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejpb.2026.115146_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2017.10.021","article-title":"Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics","volume":"54","author":"Fletcher","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejpb.2026.115146_b0095","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.2147\/IJN.S136453","article-title":"Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model","volume":"12","author":"Wolf-Grosse","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115146_b0100","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/14686996.2019.1625721","article-title":"A Human whole-blood model to study the activation of innate immunity system triggered by nanoparticles as a demonstrator for toxicity","volume":"20","author":"Ekdahl","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.ejpb.2026.115146_b0105","article-title":"Liposomes - human phagocytes interplay in whole blood: effect of liposome design","volume":"54","author":"Giambelluca","year":"2023","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115146_b0110","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2024.12.019","article-title":"mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions","volume":"33","author":"Nguyen","year":"2025","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115146_b0115","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17425247.2015.1009444","article-title":"Monocyte Targeting and Activation by Cationic Liposomes Formulated with a TLR7 Agonist","volume":"12","author":"Johansen","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"33","key":"10.1016\/j.ejpb.2026.115146_b0120","article-title":"Cellular Interactions of Liposomes and PISA Nanoparticles during Human Blood Flow in a Microvascular Network","volume":"16","author":"Vu","year":"2020","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115146_b0125","first-page":"119","article-title":"Interaction of Liposomes with Human Leukocytes in whole Blood. Biochimica et Biophysica Acta (BBA) - Molecular","volume":"762","author":"Kuhn","year":"1983","journal-title":"Cell Res."},{"issue":"42","key":"10.1016\/j.ejpb.2026.115146_b0130","doi-asserted-by":"crossref","first-page":"29021","DOI":"10.1021\/acsnano.4c09919","article-title":"Patient-specific Nanoparticle Targeting in Human Leukemia Blood","volume":"18","author":"Ju","year":"2024","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.ejpb.2026.115146_b0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41578-024-00658-1","article-title":"In Vivo Biomolecule Corona and the Transformation of a Foe into an Ally for Nanomedicine","volume":"9","author":"Hadjidemetriou","year":"2024","journal-title":"Nat. Rev. Mater."},{"issue":"24","key":"10.1016\/j.ejpb.2026.115146_b0140","first-page":"00050","article-title":"Quality Assessment of LNP-RNA Therapeutics with Orthogonal Analytical Techniques","volume":"S0168\u20133659","author":"Parot","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115146_b0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ejpb.2021.03.004","article-title":"Improved Multidetector Asymmetrical-Flow Field-Flow Fractionation Method for Particle Sizing and Concentration Measurements of Lipid-based Nanocarriers for RNA delivery","volume":"163","author":"Mildner","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115146_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2025.465663","article-title":"Frit-Inlet Asymmetric Flow Field-Flow Fractionation for the Analysis of Lipid Nanoparticle-Protein Interactions","volume":"1743","author":"Abdulrahman","year":"2025","journal-title":"J. Chromatogr. A"},{"issue":"14","key":"10.1016\/j.ejpb.2026.115146_b0155","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.3390\/nano12142446","article-title":"In Cellulo and In Vivo Comparison of Cholesterol, Beta-Sitosterol and Dioleylphosphatidylethanolamine for Lipid Nanoparticle Formulation of mRNA","volume":"12","author":"Medjmedj","year":"2022","journal-title":"Nanomaterials (basel)"},{"key":"10.1016\/j.ejpb.2026.115146_b0160","series-title":"Autoimmunity: from Bench to Bedside [internet]","article-title":"Introduction to T and B Lymphocytes","author":"Cano","year":"2013"},{"key":"10.1016\/j.ejpb.2026.115146_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954936","article-title":"Role of B Cells as Antigen Presenting Cells","volume":"13","author":"Rastogi","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115146_b0170","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ni1389","article-title":"B Lymphocytes from Early Vertebrates have Potent Phagocytic and Microbicidal Abilities","volume":"7","author":"Li","year":"2006","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115146_b0175","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846016","article-title":"Antigen Phagocytosis by B Cells is Required for a Potent Humoral Response","volume":"19","author":"Mart\u00ednez-Ria\u00f1o","year":"2018","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115146_b0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.imbio.2015.12.003","article-title":"Human B Cells have an active Phagocytic Capability and Undergo Immune Activation upon Phagocytosis of Mycobacterium Tuberculosis","volume":"221","author":"Zhu","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.ejpb.2026.115146_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892169","article-title":"The Ins and Outs of Antigen Uptake in B Cells","volume":"13","author":"McShane","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115146_b0190","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in Lipid Nanoparticles and their Safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines (basel)"},{"issue":"12","key":"10.1016\/j.ejpb.2026.115146_b0195","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/pharmaceutics16121521","article-title":"Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on their Interaction with the Immune System","volume":"16","author":"Catenacci","year":"2024","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115146_b0200","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.3390\/ijms25073595","article-title":"mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to adverse Reactions","volume":"25","author":"Bakos","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115146_b0205","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1038\/ncomms5277","article-title":"Degradable Lipid Nanoparticles with Predictable in Vivo siRNA delivery activity","volume":"5","author":"Whitehead","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2026.115146_b0210","article-title":"Impact of Administration Routes and Dose Frequency on the Toxicology of SARS-CoV-2 mRNA Vaccines in mice Model","author":"Ahn","year":"2024","journal-title":"Arch. Toxicol."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115146_b0215","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","article-title":"Engineering Lipid Nanoparticles for Enhanced Intracellular delivery of mRNA through Inhalation","volume":"16","author":"Kim","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2026.115146_b0220","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9241090","article-title":"\u03b2-Sitosterol Suppresses LPS-Induced Cytokine Production in Human Umbilical Vein Endothelial Cells via MAPKs and NF-\u03baB Signaling Pathway","volume":"2023","author":"Bi","year":"2023","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115146_b0225","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41401-020-0403-9","article-title":"\u03b2-Sitosterol Ameliorates Influenza a Virus-Induced Proinflammatory Response and Acute Lung Injury in mice by Disrupting the Cross-talk between RIG-I and IFN\/STAT Signaling","volume":"41","author":"Zhou","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejpb.2026.115146_b0230","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41467-020-14527-2","article-title":"Naturally-Occurring Cholesterol Analogues in Lipid Nanoparticles Induce Polymorphic Shape and Enhance Intracellular delivery of mRNA","volume":"11","author":"Patel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejpb.2026.115146_b0235","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1038\/mtna.2014.61","article-title":"Shielding of Lipid Nanoparticles for siRNA delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy","volume":"3","author":"Kumar","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115146_b0240","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","article-title":"TNF Alpha and the TNF Receptor Superfamily: Structure-Function Relationship(s)","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsc. Res. Tech."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115146_b0245","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The Role of Tumor Necrosis factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115146_b0250","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/cancers13030564","article-title":"Harnessing Tumor Necrosis factor Alpha to Achieve Effective Cancer Immunotherapy","volume":"13","author":"Mercogliano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ejpb.2026.115146_b0255","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1039\/D2BM01846B","article-title":"Analysis of PEG-Lipid Anchor Length on Lipid Nanoparticle Pharmacokinetics and activity in a Mouse Model of Traumatic Brain Injury","volume":"11","author":"Waggoner","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejpb.2026.115146_b0260","unstructured":"Mui, B. L. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Molecular Therapy."},{"issue":"22","key":"10.1016\/j.ejpb.2026.115146_b0265","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/add482","article-title":"mRNA Lipid Nanoparticles in CAR-T Therapy: a Novel Strategy to Improve Efficacy","volume":"36","author":"Zhao","year":"2025","journal-title":"Nanotechnology"},{"issue":"8","key":"10.1016\/j.ejpb.2026.115146_b0270","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1073\/pnas.1620874114","article-title":"Barcoded Nanoparticles for High Throughput in Vivo Discovery of Targeted Therapeutics","volume":"114","author":"Dahlman","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2026.115146_b0275","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jconrel.2023.04.005","article-title":"High-throughput screens identify a lipid nanoparticle that preferentially delivers mRNA to human tumors in vivo","volume":"357","author":"Huayamares","year":"2023","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:41:13Z","timestamp":1790109673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"alternative-id":["S0939641126001670"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115146","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions between mRNA lipid nanoparticles and immune cells in fresh human whole blood","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115146"}}